Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$596.92 USD

596.92
2,138,161

+3.13 (0.53%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Thermo Fisher's Patheon Buyout Gains Antitrust Clearance

Thermo Fisher (TMO) gets antitrust clearance to move a step closer toward completion of Patheon acquisition.

    AmerisourceBergen (ABC) Q3 Earnings: Will It Disappoint?

    AmerisourceBergen's (ABC) third-quarter performance face risks from reduced contract renewals and lower generic inflation.

      Zimmer (ZBH) Tops Q2 Earnings, Drops View on Dull Sales

      Zimmer Biomet's (ZBH) Q2 earnings results disappoint with an unimpressive Knee, Hip and Dental performances.

        Boston Scientific (BSX) Tops Q2 Earnings & Sales, View Up

        Boston Scientific's (BSX) Q2 results gain on balanced segmental growth. Currency remains a dampener though.

          Thermo Fisher (TMO) Tops Q2 Earnings & Revenues, View Up

          Thermo Fisher Scientific (TMO) continues to gain considerable synergies from FEI Company acquisition. A raised guidance buoys optimism.

            Thermo Fisher (TMO) Beats on Q2 Earnings & Sales Estimates

            Thermo Fisher (TMO) rides high in Q2 banking on its analytical instruments segment in particular.

              Quest Diagnostics (DGX) Tops Q2 Earnings, Raises '17 View

              Quest Diagnostics (DGX) continues to ride high on its advanced diagnostic offerings. Also, a raised view buoys optimism.

                Medical Instruments' Jul 26 Earnings Lineup: EW, TMO, VAR

                The ongoing political conflict resulting in a delay in policy implementation is a major dampener for Q2 earnings in the Medical space.

                  Should You Buy Thermo Fisher Scientific Inc. (TMO) Ahead of Earnings?

                  Thermo Fisher Scientific Inc. (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.

                    Can Henry Schein (HSIC) Spring a Surprise in Q2 Earnings?

                    The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.

                      What's in the Offing for Hologic (HOLX) in Q3 Earnings?

                      Hologic's (HOLX) gain through product launch and Cynosure integration may get hampered by a dull Cytology performance.

                        Can Illumina (ILMN) Spring a Surprise this Earnings Season?

                        Illumina (ILMN) is well poised to witness steady top-line growth in Q2. Yet, the bottom line may remain stressed.

                          What's in the Cards for DaVita (DVA) this Earnings Season?

                          Despite a stable Kidney Care business, escalating expenses is likely to mar DaVita's (DVA) performance in the second quarter.

                            Will Stryker (SYK) Deliver a Beat this Earnings Season?

                            The growing adoption of Stryker's (SYK) MAKO robots is expected to drive second-quarter 2017 sales in the orthopedic and reconstructive surgery market.

                              Is a Surprise in Store for ResMed (RMD) in Q4 Earnings?

                              Currency headwind is likely to dampen ResMed's (RMD) gains in the COPD and sleep apnea market.

                                Boston Scientific (BSX) Q2 Earnings: What Awaits the Stock?

                                Lower TAVR sales due to recall of Lotus valves within the European and other key markets is likely to mar Boston Scientific's (BSX) top-line performance in Q2.

                                  McKesson (MCK) Q1 Earnings: Stock Likely to Beat Estimates?

                                  McKesson's (MCK) strategic acquisitions and promising guidance raise optimism for the first quarter of fiscal 2018.

                                    IDEXX Laboratories (IDXX) Q2 Earnings: A Beat in the Cards?

                                    IDEXX Laboratories' (IDXX) Companion Animal Group business might drive its performance in Q2.

                                      LabCorp (LH) Q2 Earnings: Is Disappointment in the Cards?

                                      With the Covance Drug Diagnostic arm's revenue and margins projected to decline further, LabCorp???s business in Q2 might face disruption.

                                        Baxter International (BAX) Q2 Earnings: What's in Store?

                                        Despite an upbeat guidance, lower cyclophosphamide sales are likely to mar Baxter International (BAX) performance in the second quarter 2017.

                                          Varian Medical (VAR) Q3 Earnings: Is a Surprise in Store?

                                          Varian Medical Systems' (VAR) oncology business strength might drive its performance in Q3.

                                            Align Technology (ALGN) Q2 Earnings: A Beat in the Cards?

                                            Align Technology (ALGN) might ride high in Q2 banking on growth in the Invisalign space.

                                              What's in Store for athenahealth (ATHN) in Q2 Earnings?

                                              athenahealth Inc. (ATHN) is set to report second-quarter 2017 results on Jul 20.

                                                Will Intuitive Surgical (ISRG) Surprise in Q2 Earnings?

                                                Intuitive Surgical Inc. (ISRG) is scheduled to report second-quarter 2017 results after the closing bell on Jul 20.

                                                  Will Thermo Fisher's (TMO) Q2 Earnings Surpass Expectations?

                                                  Strong focus on product launch and emerging market expansion should drive Thermo Fisher (TMO) toward an earnings beat in Q2.